{"id":"apatinib-etoposide-and-cisplatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hand-foot skin reaction"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL2447941","moleculeType":"Small molecule","molecularWeight":"629.38"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Apatinib selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), blocking tumor neovascularization and reducing blood supply to cancer cells. Etoposide is a topoisomerase II inhibitor that causes DNA strand breaks, while cisplatin is a platinum-based alkylating agent that cross-links DNA. The combination leverages anti-angiogenic and cytotoxic mechanisms to enhance therapeutic efficacy.","oneSentence":"This combination uses apatinib (a tyrosine kinase inhibitor targeting VEGFR2) alongside etoposide and cisplatin (chemotherapy agents) to inhibit tumor angiogenesis while simultaneously inducing DNA damage and apoptosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:03.164Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer (Phase 3 investigation)"},{"name":"Advanced or metastatic malignancies (investigational)"}]},"trialDetails":[{"nctId":"NCT05139095","phase":"PHASE2","title":"Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-01-27","conditions":"Gestational Trophoblastic Neoplasia","enrollment":70},{"nctId":"NCT06764368","phase":"PHASE2","title":"Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-01-01","conditions":"Neuroendocrine Tumors","enrollment":39},{"nctId":"NCT06480864","phase":"NA","title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Yunpeng Liu","startDate":"2024-08-09","conditions":"Small Cell Lung Cancer","enrollment":38},{"nctId":"NCT05142865","phase":"PHASE2","title":"Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2022-01-14","conditions":"Advanced or Metastatic EP-NEC","enrollment":30},{"nctId":"NCT04490421","phase":"PHASE3","title":"Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.","status":"UNKNOWN","sponsor":"Fuzhou General Hospital","startDate":"2020-08-01","conditions":"Lung Neoplasm, Small Cell Lung Cancer, PD-1 Inhibitors","enrollment":45},{"nctId":"NCT03100955","phase":"PHASE3","title":"A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Qingdao University","startDate":"2017-03-01","conditions":"Progression Free Survival","enrollment":120},{"nctId":"NCT02875457","phase":"PHASE3","title":"Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin","status":"UNKNOWN","sponsor":"Third Military Medical University","startDate":"2016-09","conditions":"Small Cell Lung Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"apatinib;etoposide and cisplatin","genericName":"apatinib;etoposide and cisplatin","companyName":"Third Military Medical University","companyId":"third-military-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses apatinib (a tyrosine kinase inhibitor targeting VEGFR2) alongside etoposide and cisplatin (chemotherapy agents) to inhibit tumor angiogenesis while simultaneously inducing DNA damage and apoptosis. Used for Small cell lung cancer (Phase 3 investigation), Advanced or metastatic malignancies (investigational).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}